Rituximab Relation to ocrelizumab

A board to discuss the anticipated multiple sclerosis treatment Rituxan.
Post Reply
User avatar
CureOrBust
Family Elder
Posts: 3374
Joined: Wed Jul 27, 2005 2:00 pm
Location: Sydney, Australia

Rituximab Relation to ocrelizumab

Post by CureOrBust »

It turns out that Rituximab patent expires in the US in 2015. This means that, by the time the phase III is over, the patent will be over too. So, no profit then in doing such an investment. To surpass this inconvenience Genentech invented a new drug, antiCD20 as well, but humanized (Rituximab is chimeric), called Ocrelizumab, and started the whole process again. Then, obviously, we got a phase II trial with ocrelizumab in MS. Results have not been published yet but have been presented at 2010 ECTRIMS meeting and show,as expected, an almost equal efficacy profile to that of rituximab. But a patient died on the ocrelizumab arm from an unexpected “systemic inflammatory syndrome”. That could be chance and still hope larger studies to be assured… but it was not chance. Several rheumatoid arthritis trials with ocrelizumab have been terminated because “the overall benefit to risk profile of ocrelizumab was not favorable in RA” what it really means that 7 patients died unexpectedly in the high ocrelizumab dose arms of the trials.
http://neuroimmunology.wordpress.com/20 ... sclerosis/

Are we to get an inferior product (ocrelizumab) because the profits are not there...
centenarian100
Family Elder
Posts: 504
Joined: Mon Apr 15, 2013 9:51 am

Re: Rituximab Relation to ocrelizumab

Post by centenarian100 »

CureOrBust wrote:
It turns out that Rituximab patent expires in the US in 2015. This means that, by the time the phase III is over, the patent will be over too. So, no profit then in doing such an investment. To surpass this inconvenience Genentech invented a new drug, antiCD20 as well, but humanized (Rituximab is chimeric), called Ocrelizumab, and started the whole process again. Then, obviously, we got a phase II trial with ocrelizumab in MS. Results have not been published yet but have been presented at 2010 ECTRIMS meeting and show,as expected, an almost equal efficacy profile to that of rituximab. But a patient died on the ocrelizumab arm from an unexpected “systemic inflammatory syndrome”. That could be chance and still hope larger studies to be assured… but it was not chance. Several rheumatoid arthritis trials with ocrelizumab have been terminated because “the overall benefit to risk profile of ocrelizumab was not favorable in RA” what it really means that 7 patients died unexpectedly in the high ocrelizumab dose arms of the trials.
http://neuroimmunology.wordpress.com/20 ... sclerosis/

Are we to get an inferior product (ocrelizumab) because the profits are not there...
Sigh...indeed.

But if the data for ocrelizumab look good, doctors could use the data but then prescribe the cheaper rituxan. :)
Post Reply
  • Similar Topics
    Replies
    Views
    Last post

Return to “Rituxan (Rituximab)”